Belgium· BE-AMP-SAM478977-00
Evotaz 300 mg - 150 mg
A atazanavir and cobicistat product containing cobicistat, registered in Belgium by Bristol-Myers Squibb Pharma. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Atazanavir and cobicistat is registered in 11 of 19 countries.
Countries holding a registration under ATC J05AR15 (atazanavir and cobicistat), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Atazanavir and cobicistat · ATC J05AR15
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Cobicistat
- Manufacturer
- Bristol-Myers Squibb Pharma
- Country
- Belgium (BE)
- ATC code
- J05AR15
- ATC class
- Atazanavir and cobicistat
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Atazanavir and cobicistat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTYBOSTGilead Sciences Ireland UC, Carrigtohill
- SpainTYBOST 150mg comprimidos recubiertos con peliculaGilead Sciences Ireland Unlimited Company
- FinlandTybostGilead Sciences Ireland UC
- United KingdomTybost 150mg tabletsGilead Sciences Ltd
- IrelandTybost 150 mg film-coated tabletsGilead Sciences Ireland UC
- NetherlandsTybost 150 mg filmomhulde tablettenGilead Sciences Ireland UC
- PolandTybostGilead Sciences Ireland UC
- SwedenTybost 150 mg Filmdragerad tablettGilead Sciences Ireland UC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tybost
- Liechtenstein · Tybost
- Norway · Tybost
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5009772d-e760-41fa-a7e3-2c8dd4966244 GET /v1/drugs/5009772d-e760-41fa-a7e3-2c8dd4966244?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Evotaz 300 mg - 150 mg",
"name_fr": "Evotaz 300 mg - 150 mg",
"name_nl": "Evotaz 300 mg - 150 mg",
"amp_code": "SAM478977-00",
"strengths": [
"150.0000",
"300.0000"
],
"pack_count": 2,
"substances": [
"Cobicistat",
"Atazanavir Sulfate",
"Atazanavir",
"Sodium Starch Glycolate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Atazanavir and Cobicistat",
"authorisation_numbers": [
"EU/1/15/1025/001",
"EU/1/15/1025/002"
]
}See everything about atazanavir and cobicistat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.